Regeneron Pharmaceuticals Comprehensive Income 2010-2025 | REGN
Regeneron Pharmaceuticals comprehensive income for the quarter ending March 31, 2025 was $0.029B, a 137.69% decline year-over-year.
- Regeneron Pharmaceuticals comprehensive income for 2024 was $-0.008B, a 90.23% decline from 2023.
- Regeneron Pharmaceuticals comprehensive income for 2023 was $-0.081B, a 66.12% decline from 2022.
- Regeneron Pharmaceuticals comprehensive income for 2022 was $-0.239B, a 811.45% increase from 2021.